Literature DB >> 17586199

Burkitt's lymphoma in a patient with adenosine deaminase deficiency-severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase.

Maitham Husain1, Eyal Grunebaum, Ahmed Naqvi, Adelle Atkinson, Bo-Yee Ngan, Alessandro Aiuti, Chaim M Roifman.   

Abstract

We describe a patient with severe combined immunodeficiency because of aberrations in adenosine deaminase (ADA) who despite adequate replacement with polyethylene glycol-linked ADA (PEG-ADA) for 13 years developed Burkitt's lymphoma. Although treatment corrected the metabolic abnormalities caused by ADA deficiency, it failed to fully restore cellular immunity.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17586199     DOI： 10.1016/j.jpeds.2007.03.059

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  9 in total

1.  Comparison of elapegademase and pegademase in ADA-deficient patients and mice.

Authors:  L Murguia-Favela; W Min; R Loves; M Leon-Ponte; E Grunebaum
Journal:  Clin Exp Immunol       Date:  2020-02-09       Impact factor: 4.330

2.  Somatic mosaicism caused by monoallelic reversion of a mutation in T cells of a patient with ADA-SCID and the effects of enzyme replacement therapy on the revertant phenotype.

Authors:  M Moncada-Vélez; A Vélez-Ortega; J Orrego; I Santisteban; J Jagadeesh; M Olivares; N Olaya; M Hershfield; F Candotti; J Franco
Journal:  Scand J Immunol       Date:  2011-11       Impact factor: 3.487

Review 3.  [Lymphoma of the ocular adnexa].

Authors:  V Kakkassery; N Stübiger; I A Adamietz; I Tischoff; A Baraniskin; I M Wunderlich
Journal:  Ophthalmologe       Date:  2015-03       Impact factor: 1.059

Review 4.  How I treat ADA deficiency.

Authors:  H Bobby Gaspar; Alessandro Aiuti; Fulvio Porta; Fabio Candotti; Michael S Hershfield; Luigi D Notarangelo
Journal:  Blood       Date:  2009-07-28       Impact factor: 22.113

Review 5.  Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency.

Authors:  Donald B Kohn; Michael S Hershfield; Jennifer M Puck; Alessandro Aiuti; Annaliesse Blincoe; H Bobby Gaspar; Luigi D Notarangelo; Eyal Grunebaum
Journal:  J Allergy Clin Immunol       Date:  2018-09-05       Impact factor: 10.793

6.  Long-Term Outcome of Adenosine Deaminase-Deficient Patients-a Single-Center Experience.

Authors:  Ori Scott; Vy Hong-Diep Kim; Brenda Reid; Anne Pham-Huy; Adelle R Atkinson; Alessandro Aiuti; Eyal Grunebaum
Journal:  J Clin Immunol       Date:  2017-07-26       Impact factor: 8.542

7.  Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID).

Authors:  Claire Booth; H Bobby Gaspar
Journal:  Biologics       Date:  2009-07-13

Review 8.  First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature.

Authors:  Maddalena Migliavacca; Andrea Assanelli; Maurilio Ponzoni; Roberta Pajno; Federica Barzaghi; Fabio Giglio; Francesca Ferrua; Marta Frittoli; Immacolata Brigida; Francesca Dionisio; Roberto Nicoletti; Miriam Casiraghi; Maria Grazia Roncarolo; Claudio Doglioni; Jacopo Peccatori; Fabio Ciceri; Maria Pia Cicalese; Alessandro Aiuti
Journal:  Front Immunol       Date:  2018-02-02       Impact factor: 7.561

9.  A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity).

Authors:  Irbaz Bin Riaz; Warda Faridi; Mrinal M Patnaik; Roshini S Abraham
Journal:  Front Immunol       Date:  2019-04-16       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.